Rekombinanter LAG3 Antikörper

Produktnummer ABIN7881490

Der Kaninchen Monoklonal anti-LAG3 Antikörper wird verwendet zum Nachweis von LAG3 in Proben von Human. Er wurde validiert für IHC, ICC und IF.

Kurzübersicht für Rekombinanter LAG3 Antikörper (ABIN7881490)

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser LAG3 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF)

Klon: 31L58

Produktdetails anti-LAG3 Antikörper

Verwendungszweck: LAG-3 Antibody / Lymphocyte activation gene 3 protein / CD223

Aufreinigung: Affinity-chromatography

Immunogen: A synthesized peptide derived from human CD223 was used as the immunogen for the LAG-3 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the LAG-3 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store the LAG-3 antibody at -20oC.

Details zu LAG3

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Andere Bezeichnung: LAG-3

Hintergrund: LAG-3 antibody detects lymphocyte activation gene 3 protein, an immune checkpoint receptor encoded by the LAG3 gene. LAG-3 is expressed on activated T cells, natural killer cells, and plasmacytoid dendritic cells. It binds MHC class II molecules and negatively regulates T cell proliferation and activation. This checkpoint function maintains immune tolerance and prevents autoimmunity, but also contributes to immune evasion in cancer.

LAG-3 antibody is widely applied in immunology, oncology, and translational research. In cancer, LAG-3 expression marks exhausted T cells within the tumor microenvironment. In chronic infection, sustained LAG-3 expression dampens antiviral responses. By detecting LAG-3, researchers can evaluate immune exhaustion, tolerance mechanisms, and therapeutic checkpoint blockade strategies.

Flow cytometry with LAG-3 antibody identifies exhausted or regulatory T cell subsets. Immunohistochemistry maps LAG-3 expression in tumors and inflamed tissues, while immunofluorescence highlights surface distribution on lymphocytes. Western blotting confirms expression in activated immune cell lysates. These methods enable detailed characterization of immune checkpoint biology.

LAG-3 has therapeutic relevance as a target for immune checkpoint inhibitors. Antibodies blocking LAG-3 restore T cell function and enhance antitumor immunity. Clinical trials are evaluating LAG-3 blockade alone and in combination with PD-1 inhibitors. By applying LAG-3 antibody, scientists can monitor expression as a biomarker for patient selection and therapeutic response.

LAG-3 is also involved in autoimmune disease and transplantation. It modulates T regulatory cell function and dendritic cell activation, influencing tolerance and graft survival. Studying LAG-3 with antibody based methods provides insights into balancing immunity and tolerance in clinical settings.

LAG-3 antibody from NSJ Bioreagents provides strong specificity for detecting this checkpoint receptor. Its performance across multiple assays supports both basic and translational research in immunology and cancer therapy.

UniProt: P18627

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints